Business Wire

MA-VERISTAT

Share
Veristat Strengthens Regulatory Capabilities Across Europe and UK

Veristat , a scientific-minded global clinical research organization (CRO), announced today the expansion of its regulatory services capabilities by acquiring Drug Development and Regulation (DDR) , a scientific and regulatory consultancy with offices in Barcelona and Amsterdam. This well-timed acquisition advances Veristat’s regulatory capacities in Europe and the United Kingdom (UK) as it works to accelerate the development of novel therapies for a growing number of biotech, pharmaceutical and medical device clients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005506/en/

Led by Founder and Chief Executive Officer, Xavier Luria, M.D.— former Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA) — DDR has carved out an impressive growth trajectory working with small to midsized companies largely involved in rare diseases and cancers, among others, and keenly interested in avoiding the implications of a less than ideal regulatory path to registration of their drugs and medical technology products. With its proficiency in European medical regulations in particular, the acquisition builds on the proven expertise of the Veristat team responsible for regulatory insight and action at a time when significant regulatory changes are afoot.

“Dr. Luria has built DDR into a company with a powerful reputation for the design, development and implementation of successful regulatory guidance, encompassing the alignment of multi-regional regulations, and proactive planning to resolve potential regulatory challenges,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “Sponsors recognize that historical regulatory pathways are evolving, and regulatory agencies worldwide are offering greater opportunities for access and partnership. Architecting the ideal approach to optimize the path to a positive regulatory outcome requires collaboration with an experienced regulatory partner. The astute abilities of our team to interact with regulators and support positive results will no doubt serve our clients well.”

With DDR, Veristat will continue to deliver a flexible regulatory service model that provides end-to-end strategy, implementation and oversight of all related activities that ensure compliance with global regulatory requirements and swift approval.

“I am pleased to welcome the exceptional DDR team to the Veristat family here in Barcelona,” stated Montse Barceló Riera, M.D., Vice President, Europe for Veristat. “ We are now able to provide our customers with a deeper understanding of the EMA and other key regulators, along with an expanded team fully committed to reducing time to market in important areas such as cell, gene, and RNA therapies.”

“Veristat exemplifies the core values DDR has embraced over the years,” stated Xavier Luria, M.D. “I am delighted to know that the company makes it a top priority to support and empower its people. Veristat is at the forefront of driving bold comprehensive clinical study strategies with a team unafraid of the big thinking required to get novel therapies to patients everywhere— quickly, safely and cost-effectively. On behalf of the entire DDR team, we look forward to supporting Veristat as a pre-eminent clinical research organization for the advancement of novel therapies across Europe, the UK, and worldwide.”

About DDR

Drug Development and Regulation (DDR) is an independent European consultancy with offices in Barcelona and Amsterdam, focused on providing appropriate scientific and regulatory expertise for the global development and registration of drugs and medical devices. The Company’s tailor-made solutions contribute to the success of clients’ development programs across quality, nonclinical, clinical, and regulatory functions. The DDR team brings a track record of regulatory prowess supporting hundreds of MAAs and Agency Briefing Meetings, fully accustomed to the utmost regulatory standards to carry out any plan, including innovative products, re-profiling or hybrid drugs among others. DDR benefits from a network of highly qualified experts and strategic collaborations with renowned institutions worldwide.

About Veristat

Veristat , a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 27 years’ experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared nearly 100 marketing applications for approval with global regulatory authorities in the last 10 years.

Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SCENTMATIC's AI "KAORIUM" Debuts at THAMEEN Fragrance Launch in London's Selfridges4.7.2025 11:13:00 CEST | Press release

SCENTMATIC Inc., a leader in scent digitalization, introduced its AI-powered scent-to-language system, KAORIUM, at the THAMEEN Fragrance new product launch event. This pivotal event took place from June 5 to 11, 2025, at Selfridges department store in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703662207/en/ State of exhibition Global Expansion: KAORIUM Establishes UK Presence Europe leads the global fragrance market, with the UK projected to reach US$2.82 billion by 2033. Recognizing this, SCENTMATIC is rapidly expanding its international footprint. In May 2024, SCENTMATIC established its overseas subsidiary, KAORIUM, in London, appointing industry expert Ben Yanoushek as CEO. Official UK operations commenced on February 1, 2025, with the launch of its dedicated website: www.kaorium.com. KAORIUM Trialed at "Florentine Diamond" Launch Event The "Florentine Diamond" launch event for luxury brand THAMEEN Frag

Andersen Consulting samarbejder med Mercurial Minds om at forbedre mulighederne inden for digital transformation4.7.2025 01:10:00 CEST | Pressemeddelelse

Andersen Consulting udvider sit udbud af teknologidrevne løsninger med tilføjelsen af samarbejdsfirmaet Mercurial Minds (M.M.), et konsulentfirma inden for digital transformation, AI og IT med base i Pakistan. M.M. blev grundlagt i 2013 og tilbyder en række tjenester, der er designet til at hjælpe organisationer med at udvikle sig og skalere, herunder i forbindelse med deres digitale transformationsstrategi, AI-tjenester, it-rådgivning og udvikling af robuste mobil- og webbrugeroplevelser. Firmaet leverer end-to-end-løsninger – udformning af datadrevne køreplaner, udvikling af intelligent automatisering og levering af sikre mobil- og weboplevelser, der kan skaleres – skræddersyet til virksomheder, der ønsker at forbedre sine forbindelsesmulighederne og opnå indsigter i realtid. M.M. betjener en bred vifte af brancher med fokus på finans, telekommunikation og andre dataintensive sektorer. "Dette samarbejde er en katalysator," siger Nabeel Saiyer, administrerende direktør for M.M. "Vores

Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 01:00:00 CEST | Press release

The World Economic Forum report, in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, predicts a significant uptick in tourist trips across the globeThe tourism sector will contribute $16 trillion to global GDP (more than 11% of the global economy) by 2034, according to World Travel & Tourism Council estimates (WTTC)India and China will be responsible for more than 25% of all outbound travel by 2030 The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster th

The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 21:00:00 CEST | Press release

The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate

Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 14:59:00 CEST | Press release

Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye